文献速递慢性肾脏病水电解质与酸碱

高剂量胆钙化醇可延缓CKD 3-4期患者继发性甲状旁腺功能亢进的进展:一项12周双盲随机对照研究

High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

结果显示胆钙化醇组钙二醇显著升高而PTH保持稳定,安慰剂组PTH升高,两组PTH平均变化差异显著(P<0.01),且无高钙血症等副作用。

要点

  • 高剂量胆钙化醇可阻止CKD 3-4期患者SHPT进展。
  • 治疗未导致高钙血症或其他副作用。
  • PTH下降30%的比例两组无差异。

核心结论

  • CKD 3-4期患者每日高剂量胆钙化醇可阻止继发性甲状旁腺功能亢进进展,且不引起高钙血症或其他副作用。

主要发现

  • 胆钙化醇组钙二醇从57.5±22升至162±49 nmol/L,PTH保持10.5±5 pmol/L;安慰剂组钙二醇稳定,PTH从13.1±9升至15.2±11 pmol/L。
  • 两组PTH平均变化差异显著(P<0.01)。
  • PTH下降30%的比例两组无差异,握力、疲劳、血磷及FGF23无影响。
  • 胆钙化醇组血钙稳定,骨化三醇大幅升高。

关键数值与推荐

  • 胆钙化醇剂量为8000 IU/日,疗程12周。
  • 纳入标准:CKD 3-4期,PTH>6.8 pmol/L,钙二醇<75 nmol/L。

临床怎么用

  • 对CKD 3-4期合并钙二醇不足及PTH升高的患者,可考虑每日高剂量胆钙化醇以延缓SHPT进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calcidiol insufficiency may accelerate the development of secondary hyperparathyroidism (SHPT). We tested the effect of a substantial increase in calcidiol on mineral metabolism in patients with chronic kidney disease (CKD). METHODS: Ninety-five patients with CKD Stages 3-4, parathyroid hormone (PTH) above 6.8 pmol/L and calcidiol below 75 nmol/L were randomized to receive either cholecalciferol 8000 IU/day or placebo for 12 weeks. The primary endpoint was difference in the mean change in iPTH after 12 weeks. The proportion of participants having a 30% reduction in PTH and the effect on hand grip strength, fatigue and different biochemical variables were also investigated. RESULTS: Baseline calcidiol was 57.5 ± 22 and 56.8 ± 22 nmol/L in the cholecalciferol and placebo groups, respectively. The corresponding concentrations of PTH were 10.9 ± 5 and 13.1 ± 9 pmol/L. Calcidiol increased to 162 ± 49 nmol/L in patients receiving cholecalciferol, and PTH levels remained constant at 10.5 ± 5 pmol/L. In the placebo group, calcidiol remained stable and PTH increased to 15.2 ± 11 pmol/L. The mean change in PTH differed significantly between the two groups (P < 0.01). The proportion of subjects reaching a 30% decrease in PTH did not differ. No effect on grip strength, fatigue, phosphate or fibroblast growth factor 23 was observed. Cholecalciferol treatment resulted in stable calcium concentrations and a substantial increase in calcitriol. CONCLUSION: Treatment with high daily doses of cholecalciferol in patients with CKD Stages 3-4 halts the progression of SHPT and does not cause hypercalcaemia or other side effects.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Westerberg PA, Sterner G, Ljunggren Ö, et al. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant. 2018. PMID: 29156056. doi:10.1093/ndt/gfx059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。